Dataset
Data used in the preparation of this article were obtained from the ADNI. The ADNI was launched in 2003 as a public–private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether MRI, positron emission tomography, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of MCI and AD22,23. All relevant tests and methods were performed in accordance with relevant guidelines and regulations, and this study was approved by the ADNI Publications Committee.
1.5 T T1-weighted baseline sMRI scans from 798 participants of the ADNI-1 cohort were included in this study (187 AD, 382 MCI, and 229 CN). The MMSE scores were significantly different between the AD, MCI, and CN groups. Table 1 shows the demographic characteristics of the three groups of participants. MCI…
